^(89)锶治疗骨转移瘤对患者肝功能的影响

Impact of ^(89)Sr therapy for bone metastases on patient' liver function

目的临床观察89锶治疗骨转移瘤对患者肝功能的影响。方法将87例骨转移瘤患者随机分为观察组39例和对照组48例。观察组静脉注射核素二氯化锶(89SrCl2)注射液治疗,3个月后可重复;对照组予吗啡缓释片口服,连服3个月。3月后对比2组治疗前后肝功能各项指标[总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转移酶(GGT)、碱性磷酸酶(ALP)]的变化情况。结果观察组治疗前后各项肝功能指标无显著变化(P>0.05);对照组治疗后肝功能指标较治疗前明显增高,差异有统计学意义(P<0.05)。结论 89锶治疗骨转移瘤,止痛效果持久且不损害肝功能,值得临床推广应用。

Objective To observe the impact of 89Sr therapy for bone metastases on patient＇ liver function. Methods 87 cases patients with bone metastases were randomly divided into observation group （39 cases） and control group （48 ca- ses）. Observation group were given the trentment of intravenous Sr chloride （89 SrC12 ） injection, repeated after 3 months ; And control group were given the trentment of oral morphine hydrochloride sustained release tablets for 3 months. After 3 months compared indicators of liver function [ total bilirubin （ TBIL）, alanine aminotransferase （ ALT）, aspartic transaminase （ AST ）, glntamyltransferase （GGT）, kalkaline phosphatase （ALP） ] before and after treatment. Results All liver function indicators of observation group were no difference before and after treatment （P 〉 0.05 ）, and the liver function indicators of control group after treatment was higher than before treatment, the difference was statistically significant （P 〈 0.05）. Conclusion The anal- gesic effect of 89 Sr therapy for bone metastases is lasting and has no harm to liver function.